Clinical Trial Update: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trial to evaluate safety, reactogenicity, and immunogenicity of Moderna's mRNA-1468 in adults aged 50 and older for herpes zoster.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• mRNA-1468 (mRNA-1468)

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Herpes Zoster | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING